[
  {
    "ts": null,
    "headline": "Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026",
    "summary": "Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue. Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million. Although investors ar",
    "url": "https://finnhub.io/api/news?id=141d91c15bda60ad8539f229fffa4d106fedfe063e09dd8d212989653fd63be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731953922,
      "headline": "Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026",
      "id": 131460668,
      "image": "https://media.zenfs.com/en/Benzinga/819dd36396d32967b695c60994bfa819",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue. Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million. Although investors ar",
      "url": "https://finnhub.io/api/news?id=141d91c15bda60ad8539f229fffa4d106fedfe063e09dd8d212989653fd63be5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f644c12739b6a7aa849a24de7b4a2d6b5d5fcea16ab67d6e2f579c223c6ddb37",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731949560,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 131488190,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f644c12739b6a7aa849a24de7b4a2d6b5d5fcea16ab67d6e2f579c223c6ddb37"
    }
  },
  {
    "ts": null,
    "headline": "Needham downgrades Biogen on slow growth of Alzheimer's drug",
    "summary": "Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.",
    "url": "https://finnhub.io/api/news?id=cedaa346f38746cb5561d79e5fa721936a44af3206859f5e3c407593c11f853f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731947432,
      "headline": "Needham downgrades Biogen on slow growth of Alzheimer's drug",
      "id": 131460669,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.",
      "url": "https://finnhub.io/api/news?id=cedaa346f38746cb5561d79e5fa721936a44af3206859f5e3c407593c11f853f"
    }
  },
  {
    "ts": null,
    "headline": "Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™",
    "summary": "OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC approval based on robust totality of evidence confirming biosimilarity to reference aflibercept in terms of quality, efficacy, and safety INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European",
    "url": "https://finnhub.io/api/news?id=af2cad451c3f54d73c40c9a6b924817821457ca0415a0bb8a1a9076a9ea38a84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731931200,
      "headline": "Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™",
      "id": 131440771,
      "image": "",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC approval based on robust totality of evidence confirming biosimilarity to reference aflibercept in terms of quality, efficacy, and safety INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European",
      "url": "https://finnhub.io/api/news?id=af2cad451c3f54d73c40c9a6b924817821457ca0415a0bb8a1a9076a9ea38a84"
    }
  },
  {
    "ts": null,
    "headline": "Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?",
    "summary": "We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheap NASDAQ stocks to invest in now. How Did The Stock Market Perform In Q3 2024? The stock market has been following an […]",
    "url": "https://finnhub.io/api/news?id=d5a5ce366739e0f9d710f25cece8a28d0341876fe708912147a250535dda22ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731921947,
      "headline": "Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?",
      "id": 131440772,
      "image": "https://media.zenfs.com/en/insidermonkey.com/19f06d2f1156978c403925aa82274a77",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheap NASDAQ stocks to invest in now. How Did The Stock Market Perform In Q3 2024? The stock market has been following an […]",
      "url": "https://finnhub.io/api/news?id=d5a5ce366739e0f9d710f25cece8a28d0341876fe708912147a250535dda22ff"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
    "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731903372,
      "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
      "id": 131438224,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/601800909/image_601800909.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91"
    }
  }
]